These patients may benefit more from aggressive medical management with high‐intensity statins and/or PCSK9 inhibitors, more aggressive control of diabetes mellitus with GLP‐1 and/or SGLT2 inhibitors, and more aggressive antiplatelet or antithrombotic medications (including rivaroxaban as demonstrated in the COMPASS trial).18 This evidence concerns the gene SLC5A2 and diabetes mellitus.